North America’s medical devices industry saw a drop of 38.60% in deal activity during November 2022
North America’s medical devices industry saw a drop of 38.60% in deal activity during November 2022, when compared with the last 12-month average, led by Johnson & Johnson’s $16.6bn acquisition of Abiomed, according to GlobalData’s deals database.
A total of 70 medical devices industry deals worth $28.9bn were announced for the region in November 2022, against the 12-month average of 114 deals.
Of all the deal types, venture financing saw most activity in November 2022 with 35 transactions, representing a 50% share for the region.
In second place was M&A with 31 deals, followed by private equity deals with four transactions, respectively capturing a 44.3% and 5.7% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $28.21bn, while private equity and venture financing deals totaled $467.67m and $231.31m, respectively.
North America medical devices industry deals in November 2022: Top deals
The top five medical devices deals accounted for 98.8% of the overall value during November 2022.
The combined value of the top five medical devices deals stood at $28.56bn, against the overall value of $28.9bn recorded for the month.
The top five medical devices industry deals of November 2022 tracked by GlobalData were:
1) Johnson & Johnson’s $16.6bn acquisition deal with Abiomed
2) The $8.9bn acquisition of Summit Health by VillageMD
3) WerfenLife’s $2bn acquisition deal with Immucor
4) The $615m acquisition of Apollo Endosurgery by Boston Scientific
5) Arsenal Capital Partners’s $449m private equity deal for 18% stake in Certara